In 2004 in England, over 50% of cancers were diagnosed at age 70 years and above, with only 0.5% in 15--24-year-olds ([Office for National Statistics, 2006](#bib14){ref-type="other"}). However, cancer is the leading disease-related cause of death in this age range ([Geraci *et al*, 2007](#bib10){ref-type="other"}). There is growing recognition that young cancer patients have special physical, social and educational needs in addition to appropriate disease-specific treatment. Risks of developing treatment-induced second malignancies and organ dysfunction are critical considerations in the young. Loss of fertility and other organ-specific cytotoxic effects and disruption to education, vocational and professional training can have a profound influence on future life ([National Collaborating Centre for Cancer, 2005](#bib13){ref-type="other"}).

Detailed national survival data for this age group have not been reported hitherto but are important for service planning and as a baseline for monitoring progress. We now describe survival trends over time and patterns of survival by age, sex and socioeconomic deprivation for a 23-year series of 13- to 24-year-olds with cancer in England.

Materials and methods
=====================

Teenagers and young adults aged 13--24 years (TYAs) diagnosed with malignancy in England, during the period 1979--2001, followed up to 31 December 2003, were included in this study. National cancer registration data on individual eligible cases were supplied by the National Cancer Intelligence Centre, Office for National Statistics, London (ONS), including dates of birth, diagnosis and follow-up, sex, histological type and primary site of cancer, Townsend deprivation index score (TDI) and vital status. Cases with vital status unknown (patient record not traced at the National Health Service Central Register) were excluded as were cases with a survival time of zero (diagnosed and died on the same day). These exclusion criteria were those applied by [Coleman *et al* (1999)](#bib7){ref-type="other"}. Cases lost to follow-up, for example, emigrated, were included up to date last known to be alive.

For cases registered from 1979 to 1994, cancer morphology was coded according to the International Classification of Diseases for Oncology, first edition (ICD-O 1) ([World Health Organization, 1976](#bib22){ref-type="other"}), and cancer site according to the ninth revision of the International Classification of Diseases (ICD 9) ([World Health Organization, 1977](#bib23){ref-type="other"}). For cases registered during the period 1995--2001, diagnoses were similarly coded according to ICD-O, second edition (ICD-O 2) ([Percy *et al*, 1990](#bib15){ref-type="other"}), and ICD tenth revision (ICD-10) ([World Health Organization, 1992](#bib24){ref-type="other"}). The cases were classified into 10 main diagnostic groups and 2--7 subgroups per main group as described previously ([Birch *et al*, 2002](#bib3){ref-type="other"}). This classification is recognised internationally as a suitable vehicle for analysing data on TYAs ([Barr *et al*, 2006](#bib2){ref-type="other"}).

We examined survival for each diagnostic subgroup by age at diagnosis (13--16, 17--20, 21--24 years), TDI, sex and calendar period (1979--1984, 1985--1989, 1990--1995, 1996--2001). Cases were divided into five groups, from the most affluent to most deprived, on the basis of the quintile of the distribution of TDIs for census ward of residence. TDIs are derived from levels of four census variables: car ownership; house ownership; overcrowding and unemployment within wards, giving a measure of material deprivation ([Townsend *et al*, 1998](#bib20){ref-type="other"}).

Five-year relative survival in each diagnostic group was calculated by dividing observed by expected survival among comparable groups in the general population ([Ederer *et al*, 1961](#bib9){ref-type="other"}). The 5-year expected survival was derived from the age, sex, deprivation and calendar year-specific national mortality rates for England ([Coleman *et al*, 1999](#bib7){ref-type="other"}). Relative survival by age, sex, calendar period and TDI was examined using Poisson regression ([Dickman *et al*, 2004](#bib8){ref-type="other"}, [Breslow and Day, 1987](#bib6){ref-type="other"}). Specified diagnostic subgroups with 250 (0.8%) or more cases as well as smaller groups of interest were examined individually. The significance level was set at 5%. Analyses were carried out using the statistical software package Stata, Version 9 ([StataCorp LP, 2005](#bib18){ref-type="other"}).

Results
=======

Survival time was available for 31 876 (94.8%) of 33 625 potentially eligible patients. During the period from 1993 (when such information became available) to 2001, 142 of 217 (65.4%) with zero survival time were registered by death certificate only. The remaining cases were hospital registrations who were diagnosed and died on the same day.

[Figure 1](#fig1){ref-type="fig"} shows that overall 5-year relative survival steadily increased throughout the study period (*P*\<0.001) from 63% in 1979--1984 to 77% in 1996--2001. The most marked increase was between the two earliest periods.

[Table 1](#tbl1){ref-type="table"} shows that 5-year relative survival was significantly better for females than males except for germ cell tumours (GCTs) and central nervous system (CNS) tumours. The pattern of survival with age varied between diagnostic groups. For GCTs in 13- to 16-years-olds, 17- to 20-year-olds and 21- to 24-year-olds, survival was 80, 87 and 90% respectively. However, for leukaemia and CNS tumours, survival was better in the youngest group (*P*\<0.001). For lymphomas, bone sarcomas, soft tissue sarcomas (STSs), melanoma and carcinomas, survival was not significantly associated with age. For leukaemia and carcinomas, the most deprived groups had the lowest survival (*P*=0.048 and 0.008, respectively). All diagnostic groups showed improvements in 5-year relative survival during the study period of between 9% (CNS) and 21% (leukaemia), except STS for which no improvement was seen.

[Tables 2](#tbl2){ref-type="table"}, [3](#tbl3){ref-type="table"}, [4](#tbl4){ref-type="table"}, [5](#tbl5){ref-type="table"} and [6](#tbl6){ref-type="table"} present the results of analyses by the major subtypes within main diagnostic groups.

[Table 2](#tbl2){ref-type="table"} shows 5-year survival of patients with haematological malignancies. For acute lymphoid leukaemia (ALL), females had a better survival than males (50 *vs* 43%, *P*=0.019), survival decreased with increasing age (*P*\<0.001) and increased by 18% during the study period from 37 to 55% (*P*\<0.001). For acute myeloid leukaemia (AML), there was an even greater improvement over time, from 27 to 50% but from a lower starting point than ALL. There were no significant differences in survival from AML by age and sex. For chronic myeloid leukaemia, there was a marked improvement in survival between the time periods 1979--1984 and 1985--1989 but no consistent further improvement. Although there was a significant trend with TDI for leukaemia overall ([Table 1](#tbl1){ref-type="table"}) there was no significant trend for any subtype of leukaemia.

For non-Hodgkin lymphoma (NHL), 13- to 16-year-olds had a better survival than 17- to 24-year-olds (*P*=0.033). There was a marked improvement in survival between 1979--84 and 1985--89 but little subsequent improvement. For Hodgkin lymphoma (HL), female patients had a small survival advantage over males (*P*=0.026), with significant improvements over time (*P*\<0.001), reaching 93% in the latest period. There was no significant trend in survival with TDI for either NHL or HL.

[Table 3](#tbl3){ref-type="table"} shows 5-year relative survival of patients with selected CNS tumours. Only astrocytomas showed decreased survival with increasing age (*P*\<0.001), and this group showed no improvement over the study period. This pattern was driven by high-grade astrocytoma (HGA), which is more common in older age groups (data not shown). For HGA, 5-year survival did not improve during the study period (*P*=0.85) and a very low survival rate of 14% was seen in the latest period. However, for low-grade astrocytoma, 5-year survival improved from 76% in 1979--1984 to 90% in 1990--1995 but with no further improvement (*P*=0.005). The 'other glioma\' group, mainly oligodendroglioma and ependymoma, showed marked improvements from 1979 to 1995 but no subsequent improvement. For medulloblastoma and supratentorial primitive neuroectodermal tumours, there were no significant differences in survival by sex, age and time period of diagnosis. No CNS tumour group showed a trend with TDI.

[Table 4](#tbl4){ref-type="table"} shows 5-year relative survivals of patients with bone tumours and STS. For osteosarcoma, females had a better prognosis than males (*P*=0.008) and survival improved significantly between 1979--84 and 1985--89 but with no improvements more recently. Thirteen- to sixteen-year-olds with Ewing sarcoma did better than 17- to 24-year-olds (*P*=0.021), with a significant improvement in survival over time (*P*=0.005), again particularly marked between 1979--1984 and 1985--1989. Rhabdomyosarcoma (RMS) survival decreased with increasing age (*P*\<0.001), with no improvement over time and 5-year survival of only 29% in the latest period. For other specified types of STS combined, there was no significant improvement in survival over time. For unspecified STSs, survival improved significantly between 1979 and 1995 but not subsequently. There were no significant trends in survival with TDI for any specified types of bone and STS.

[Table 5](#tbl5){ref-type="table"} shows 5-year relative survivals among patients with GCTs by primary site. For testicular GCTs, survival increased with advancing age at diagnosis (*P*\<0.001). There was a consistent improvement in 5-year survival over time (*P*\<0.001), reaching 96% in the latest period. Ovarian GCTs showed similar patterns of survival. For CNS GCTs, there were no significant differences in survival by sex, age and period of diagnosis. For GCTs of other sites, females had a substantially superior 5-year survival (*P*\<0.001). None of the subgroups showed a trend with TDI.

[Table 6](#tbl6){ref-type="table"} shows 5-year relative survivals of patients with carcinomas of selected sites. For head and neck carcinomas (excluding thyroid), females had a better survival than males (*P*=0.001). There was a trend of decreasing survival with increasing deprivation, but no trend with age. Survival steadily improved over time (*P*=0.003). Thyroid carcinoma showed a 97% or higher survival throughout the study period, with no significant variations in age, sex and deprivation (data not shown). For carcinoma of lung, there was a significant improvement over time (*P*=0.046) and females had a higher survival (*P*=0.052). For carcinoma of breast, survival decreased with increasing age but the number of cases below age 21 years was very small. There was a borderline significant trend for improved survival over time (*P*=0.055). For ovarian carcinoma, there was a marked improvement in survival between 1990--1995 and 1996--2001. This may in part reflect changes in coding between ICD-O1 and ICD-O2 so that additional, lower-grade ovarian tumours were included in the 1996--2001 data. No trend with age was seen. Carcinoma of cervix showed a marked improvement between 1979--84 and 1985--89 (*P*=0.012), but survival has remained at the same level since. For colorectal carcinomas, females had a substantially better survival than males (*P*\<0.001). Survival increased significantly over time, particularly in the most recent period. The most deprived group had the lowest survival (*P*=0.001). Numbers of carcinomas of other sites were too small for separate analysis.

Discussion
==========

This study presents the first national data for England on cancer survival among TYAs. It is now acknowledged that the special needs of cancer patients aged 0--18 years would be best served by principal treatment centres providing age-appropriate facilities and managed by dedicated multidisciplinary teams ([National Collaborating Centre for Cancer, 2005](#bib13){ref-type="other"}). For 19- to 24-year-olds, unhindered access to such expert teams is recommended. It has been suggested that in this age group in the United States, low recruitment to clinical trials contributes to the comparatively poor improvements in cancer survival ([Bleyer *et al*, 2007](#bib5){ref-type="other"}). A recent study has compared clinical trial inclusion rates of children with those of TYAs in Great Britain who have cancers relevant to both age ranges and for which phase III trials are in progress (leukaemia, lymphoma, CNS tumours, sarcoma and testicular GCT). Results for cases diagnosed in 2005--2007 show that 56% of total incident cases aged 5--14 years are entered into trials compared with only 20% of 15- to 24-year-olds. Trial inclusion for CNS tumours was particularly low ([Whelan and Fern, 2008](#bib21){ref-type="other"}). The baseline data on survival trends presented here are of importance in monitoring future progress in cancer survival in TYAs and assessing the impact of new specialist TYA cancer units, including recruitment to clinical trials.

In this study, we have analysed survival by predefined morphological groups of cancers, appropriate to the TYA age range, using national data covering more than 30 000 incident cases over a 23-year period. Overall, there were marked improvements in survival during the study period especially for all subgroups of leukaemia and NHL. However, for certain other groups, the results are less encouraging. Both osteosarcoma and Ewing sarcoma showed a step change in survival between the two early periods but then no further increase after 1989. There was no improvement for RMS and other STS. Although survival among children diagnosed with osteosarcoma up to 1997 in Britain was only slightly better than that in TYAs reported here, children with Ewing sarcoma and RMS showed more marked improvements and better survivals than their TYA counterparts ([Stiller *et al*, 2006](#bib19){ref-type="other"}; [Pastore *et al*, 2006](#bib16){ref-type="other"}). During 1993--1997, in children 5-year survival was 67% for Ewing sarcoma and 65% for RMS, but in TYAs during 1996--2001, the respective survivals were 42 and 29%. For RMS, this may partly be due to a higher proportion of TYA patients with more aggressive histologies, but this cannot entirely explain the poor outcomes in TYAs with bone and soft tissue sarcomas in general.

High-grade CNS tumours in TYAs showed little or no improvements in survival during the study period, and this was also the case for British children up to 1997 with comparable tumours ([Peris-Bonet *et al*, 2006](#bib17){ref-type="other"}). Clearly, the clinical management of high-grade CNS tumours in young people presents a major challenge. In contrast, these results show consistently high survival rates for GCTs, with equivalent improvement in 5-year survival for both testicular and ovarian tumours. Across all ages, nearly all testicular tumours are of germ-cell origin, so that the high survival rates previously reported for testicular cancer can be interpreted as survival from GCTs of the testis. However, most ovarian cancers are carcinomas, and survival rates for ovarian cancer ([Coleman *et al*, 1999](#bib7){ref-type="other"}) do not reflect survival from ovarian GCTs. This is particularly important in TYAs, as GCTs are the predominant ovarian malignancy in this age group ([Birch *et al*, 2003](#bib4){ref-type="other"}).

About 80% of cancers overall are carcinomas, but these constitute only 16% of TYA cancers ([Alston *et al*, 2007](#bib1){ref-type="other"}). Carcinomas of most sites in the present series show favourable survival rates compared with cancers at those sites across all ages ([Coleman *et al*, 1999](#bib7){ref-type="other"}). This suggests that the TYA cases may have histologically lower-grade tumours than older cases and/or differ biologically. However, survival from breast carcinoma in TYAs is similar to breast cancer in general ([Coleman *et al*, 1999](#bib7){ref-type="other"}). Females have higher survival rates for most types of cancer, and this holds true for TYAs; possible explanations include earlier presentation in females and less aggressive tumour biology.

Cancer survival rates among older patients in England and Wales are strongly influenced by socioeconomic status ([Coleman *et al*, 1999](#bib7){ref-type="other"}), but only small non-significant differences were seen in children. In this study, most cancers showed no association between TDI and survival, but for leukaemias and carcinomas overall, there were significant trends towards poorer survival with increasing deprivation, particularly for colorectal and head and neck carcinomas. These latter cancers, which show marked associations between survival and deprivation in older patients ([Coleman *et al*, 1999](#bib7){ref-type="other"}), are aetiologically linked to lifestyle factors also associated with deprivation, such as tobacco smoking and poor diet ([IARC, 1986](#bib11){ref-type="other"}; [Key *et al*, 2004](#bib12){ref-type="other"}). These factors may influence survival due to general poor health. Other considerations include speed of seeking medical healthcare, referral patterns and clinical management in socioeconomically deprived areas.

In conclusion, although there were marked increases in survival over time for all cancers combined, for some diagnostic groups, little or no improvements were seen. These results provide baseline data against which to compare outcomes in patients treated in the developing specialist TYA cancer units and in those entered into clinical trials. The data serve to identify the patient groups that present the greatest clinical challenges.
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###### 

Five-year relative survival (%) of patients diagnosed at age 13--24 during 1979--2001 in England by main diagnostic group

                        **All**   **Leukaemia**   **Lymphoma**   **CNS**   **Bone sarcomas**   **STS**   **GCTs**   **Melanoma**   **Carcinomas**                                                                                                                          
  --------------------- --------- --------------- -------------- --------- ------------------- --------- ---------- -------------- ---------------- ------ ---- --------- ------ ---- --------- ----- ---- ------- ------ ---- --------- ------ ---- --------- ------ ---- ---------
  *Sex*                                                                                                                                                                                                                                                                    
   Male                 17 339    69              \<0.001        2129      42                  0.016     4607       80             \<0.001          1777   59   0.122     1170   46   0.019     950   52   0.012   4022   89   0.730     928    78   \<0.001   1548   63   \<0.001
   Female               14 433    73                             1393      47                            3583       84                              1382   62             769    52             793   58           520    86             1768   89             3931   76    
                                                                                                                                                                                                                                                                            
  *Age (years)*                                                                                                                                                                                                                                                            
   13--16               6682      65              \<0.001        1303      47                  \<0.001   1644       82             0.772            1092   68   \<0.001   815    48   0.611     495   58   0.455   381    80   \<0.001   244    89   0.158     600    70   0.920
   17--20               10 107    70                             1194      42                            2948       81                              922    61             716    46             611   51           1386   87             786    84             1363   73    
   21--24               14 983    74                             1025      40                            3598       82                              1145   53             408    54             637   55           2775   90             1666   85             3516   72    
                                                                                                                                                                                                                                                                            
  *Deprivation*                                                                                                                                                                                                                                                            
   Most affluent        6353      71              0.001          700       45                  0.048     1705       83             0.073            653    61   0.914     408    50   0.904     346   51   0.844   916    87   0.212     595    86   0.861     928    73   0.008
   2                    6353      71                             725       46                            1635       82                              661    60             412    48             320   55           919    89             584    85             1011   73    
   3                    6355      72                             668       42                            1663       82                              648    62             366    47             339   60           914    89             571    85             1101   73    
   4                    6355      71                             723       43                            1570       82                              599    60             394    48             384   53           884    89             514    83             1168   73    
   Most deprived        6356      70                             706       41                            1617       80                              598    60             359    51             354   53           909    89             432    87             1271   69    
                                                                                                                                                                                                                                                                            
  *Year of diagnosis*                                                                                                                                                                                                                                                      
   1979--1984           7509      62              \<0.001        935       33                  \<0.001   2031       77             \<0.001          763    54   \<0.001   544    39   \<0.001   424   53   0.152   924    80   \<0.001   454    74   \<0.001   1309   64   \<0.001
   1985--1989           7482      71                             789       43                            2064       82                              718    61             446    55             426   53           1063   85             606    86             1224   71    
   1990--1995           8488      73                             929       47                            2121       83                              869    64             468    52             447   55           1220   92             850    86             1432   74    
   1996--2001           8293      77                             869       54                            1974       86                              809    63             481    51             446   56           1335   94             786    90             1514   78    

CNS=central nervous system tumours; GCTs=germ-cell tumours; STS=soft tissue sarcoma.

###### 

Five-year relative survival (%) of patients with haematological malignancies^a^ diagnosed at age 13--24 during 1979--2001 in England

                        **ALL**   **AML**   **CML**   **NHL**   **HL**                                                                  
  --------------------- --------- --------- --------- --------- -------- --------- ----- ---- ------- ------ ---- --------- ------ ---- ---------
  *Sex*                                                                                                                                 
   Male                 1163      43        0.019     671       36       0.074     178   50   0.690   1552   65   0.206     3055   87   0.026
   Female               633       50                  565       42                 116   54           789    68             2794   89    
                                                                                                                                         
  *Age (years)*                                                                                                                         
   13--16               869       50        \<0.001   333       40       0.536     54    43   0.372   599    70   0.033     1045   89   0.550
   17--20               581       44                  439       39                 94    54           816    65             2132   88    
   21--24               346       37                  464       38                 146   54           926    66             2672   88    
                                                                                                                                         
  *Deprivation*                                                                                                                         
   Most affluent        361       48        0.066     255       39       0.253     45    73   0.173   457    62   0.813     1248   90   0.190
   2                    400       48                  240       43                 53    43           452    69             1183   86    
   3                    313       48                  260       35                 52    47           453    69             1210   86    
   4                    371       43                  252       41                 62    51           457    66             1113   89    
   Most deprived        351       42                  229       36                 82    50           522    65             1095   87    
                                                                                                                                         
  *Year of diagnosis*                                                                                                                   
   1979--1984           490       37        \<0.001   311       27       \<0.001   64    30   0.002   506    52   \<0.001   1525   85   \<0.001
   1985--1989           416       45                  259       34                 71    62           569    70             1495   86    
   1990--1995           457       48                  351       43                 77    51           629    68             1492   89    
   1996--2001           433       55                  315       50                 82    66           637    72             1337   93    

ALL=acute lymphoid leukaemia; AML=acute myeloid leukaemia; CML=chronic myeloid leukaemia; HL=Hodgkin lymphoma; NHL=non-Hodgkin lymphoma.

Excluding 196 cases with other rare and unspecified haematological malignancies.

###### 

Five-year relative survival (%) of patients with selected CNS tumours diagnosed at age 13--24 during 1979--2001 in England

                        **Astrocytoma**   **Other glioma**   **Ependymoma**   **PNET**   **Other specified and unspecified**                                                            
  --------------------- ----------------- ------------------ ---------------- ---------- ------------------------------------- ------- ----- ---- ------- ----- ---- ------- ----- ---- -------
  *Sex*                                                                                                                                                                                 
   Male                 869               60                 0.439            376        53                                    0.125   141   76   0.291   191   51   0.295   200   60   0.092
   Female               749               59                                  251        61                                            110   84           117   57           155   69    
                                                                                                                                                                                         
  *Age (years)*                                                                                                                                                                         
   13--16               574               71                 \<0.001          183        62                                    0.249   94    77   0.196   129   60   0.058   112   68   0.383
   17--20               480               61                                  179        56                                            77    81           89    49           97    66    
   21--24               564               47                                  265        53                                            80    82           90    49           146   59    
                                                                                                                                                                                         
  *Deprivation*                                                                                                                                                                         
   Most affluent        335               59                 0.830            129        59                                    0.921   52    83   0.246   62    53   0.750   75    64   0.623
   2                    328               60                                  123        57                                            54    85           74    55           82    54    
   3                    324               61                                  134        57                                            52    76           65    59           73    68    
   4                    312               61                                  131        49                                            44    78           48    50           64    67    
   Most deprived        319               57                                  110        62                                            49    75           59    49           61    67    
                                                                                                                                                                                         
  *Year of diagnosis*                                                                                                                                                                   
   1979--1984           359               56                 0.199            184        49                                    0.002   64    71   0.014   78    50   0.118   78    49   0.006
   1985--1989           347               62                                  153        55                                            62    74           66    46           90    69    
   1990--1995           443               60                                  159        64                                            61    89           77    59           129   65    
   1996--2001           469               59                                  131        61                                            64    85           87    61           58    74    

PNET=medulloblastoma and primitive neuroectodermal tumours.

###### 

Five-year relative survival (%) of patients with bone and soft tissue sarcomas diagnosed at age 13--24 during 1979--2001 in England

                        **Osteosarcoma**   **Ewing sarcoma**   **RMS**   **Other specified STS**   **Unspecified STS**                                                              
  --------------------- ------------------ ------------------- --------- ------------------------- --------------------- ------- ----- ---- --------- ----- ---- ------- ----- ---- -------
  *Sex*                                                                                                                                                                             
   Male                 638                44                  0.008     356                       37                    0.990   241   31   0.329     403   57   0.446   188   51   0.069
   Female               407                53                            215                       39                            161   38             397   61           133   58    
                                                                                                                                                                                     
  *Age (years)*                                                                                                                                                                     
   13--16               480                47                  0.810     247                       44                    0.021   172   42   \<0.001   191   67   0.065   80    59   0.159
   17--20               394                48                            207                       30                            159   30             276   56           112   55    
   21--24               171                48                            117                       38                            71    25             333   56           129   51    
                                                                                                                                                                                     
  *Deprivation*                                                                                                                                                                     
   Most affluent        216                48                  0.996     118                       42                    0.974   92    33   0.733     157   58   0.258   62    50   0.063
   2                    216                46                            127                       35                            71    41             149   63           58    45    
   3                    198                46                            117                       37                            76    34             148   61           68    62    
   4                    215                48                            114                       34                            82    28             177   57           77    56    
   Most deprived        200                48                            95                        41                            81    36             169   55           56    57    
                                                                                                                                                                                     
  *Year of diagnosis*                                                                                                                                                               
   1979--1984           311                38                  \<0.001   152                       26                    0.005   92    33   0.430     153   58   0.294   71    44   0.007
   1985--1989           235                55                            124                       41                            122   39             168   56           77    49    
   1990--1995           246                50                            138                       43                            99    33             217   57           98    61    
   1996--2001           253                49                            157                       42                            89    29             262   62           75    59    

RMS=rhabodomyosarcoma; STS=soft tissue sarcoma.

###### 

Five-year relative survival (%) of patients with GCTs diagnosed at age 13--24 during 1979--2001 in England

                        **Testis**   **Ovary**   **CNS**   **Others**                                                
  --------------------- ------------ ----------- --------- ------------ ---- --------- ----- ---- ------- ----- ---- ---------
  *Sex*                                                                                                              
   Male                 3788         90                                                132   73   0.260   102   51   \<0.001
   Female                                                  417          87             26    81           77    85    
                                                                                                                      
  *Age (years)*                                                                                                      
   13--16               155          83          \<0.001   142          83   0.120     63    76   0.329   21    57   0.348
   17--20               1120         89                    145          87             54    80           67    64    
   21--24               2513         92                    130          90             41    66           91    68    
                                                                                                                      
  *Deprivation*                                                                                                      
   Most affluent        755          89          0.267     97           82   0.716     35    77   0.413   29    45   0.246
   2                    775          90                    72           90             37    81           35    71    
   3                    763          92                    81           86             33    69           37    65    
   4                    742          91                    84           89             22    78           36    69    
   Most deprived        753          91                    83           85             31    68           42    72    
                                                                                                                      
  *Year of diagnosis*                                                                                                
   1979--1984           734          83          \<0.001   105          72   \<0.001   29    66   0.178   56    63   0.083
   1985--1989           908          87                    86           85             28    64           41    59    
   1990--1995           1010         93                    109          94             57    83           44    71    
   1996--2001           1136         96                    117          94             44    77           38    71    

###### 

Five-year relative survival (%) of patients with selected carcinoma diagnosed at age 13--24 during 1979--2001 in England

                        **Head and neck^a^**   **Lung**   **Female breast**   **Ovary**   **Cervix**   **Colorectal**   **Other GU**   **Other GI**                                                                                                    
  --------------------- ---------------------- ---------- ------------------- ----------- ------------ ---------------- -------------- -------------- ------- ----- ---- ------- ----- ---- ------- ----- ---- --------- ----- ---- ------- ----- ---- ---------
  *Sex*                                                                                                                                                                                                                                                
   Male                 305                    70         0.001               80          46           0.052                                                                                        268   52   \<0.001   312   83   0.002   177   25   0.956
   Female               271                    82                             66          63                            458            61                     572   79           886   79           281   69             206   72           166   20    
                                                                                                                                                                                                                                                        
  *Age (years)*                                                                                                                                                                                                                                        
  13--16                143                    74         0.375               17          64           0.433            10             70             0.041   43    78   0.425   5     60   0.293   86    60   0.090     43    67   0.003   48    28   0.055
  17--20                186                    72                             32          56                            57             75                     164   84           75    87           164   60             138   73           104   27    
  21--24                247                    80                             97          51                            391            58                     365   76           806   78           299   62             337   82           191   19    
                                                                                                                                                                                                                                                        
  *Deprivation*                                                                                                                                                                                                                                        
   Most affluent        102                    82         0.034               24          57           0.109            77             57             0.985   111   72   0.258   103   82   0.703   108   66   0.001     99    81   0.299   53    24   0.842
   2                    111                    75                             23          65                            104            62                     101   85           142   76           100   71             93    77           61    26    
   3                    111                    78                             27          63                            78             65                     112   78           188   78           113   59             110   82           68    20    
   4                    122                    76                             35          59                            104            56                     117   76           206   81           98    65             104   79           82    21    
   Most deprived        130                    69                             37          32                            95             62                     131   83           247   78           130   48             112   74           79    24    
                                                                                                                                                                                                                                                        
  *Year of diagnosis*                                                                                                                                                                                                                                  
   1979--1984           146                    67         0.003               39          46           0.046            103            53             0.055   119   75   0.013   199   69   0.012   127   54   0.003     132   73   0.091   93    19   \<0.001
   1985--1989           120                    74                             28          50                            113            63                     119   76           219   81           111   58             124   83           83    22    
   1990--1995           137                    78                             40          50                            127            62                     138   73           243   84           124   58             160   78           83    19    
   1996--2001           173                    83                             39          67                            115            64                     196   87           225   80           187   70             102   83           84    31    

Excluding thyroid.
